The Phase 1b trial consisted of 24 patients with Parkinson’s disease, who received twice-weekly dosing of either HER-096 or placebo over a four-week period. The trial’s exploratory biomarker program ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback